Clinical trial
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
NCT01556997 is registered in ClinicalTrials.gov with Symplmed Pharmaceuticals LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
- Lead sponsor
- Symplmed Pharmaceuticals LLC
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- February 29, 2012
- Completion date
- February 28, 2013
- Enrollment
- 837 (actual)
- Sites
- 48
Conditions
As the registry lists them; a condition with its own page is linked.